BETABiohacksAI is a research tool for informational purposes only. All outputs are computational hypothesis candidates — not confirmed mechanisms, not medical advice, and not a substitute for professional medical judgment. Independent experimental validation is always required.
BiohacksAI is an evolving scientific literature platform. New compounds and evidence are indexed continuously.
B
○

Ticagrelor

An adenosine triphosphate analogue and reversible P2Y12 PURINORECEPTOR antagonist that inhibits ADP-mediated PLATELET AGGREGATION. It is used for the prevention of THROMBOEMBOLISM by patients with ACUTE CORONARY SYNDROME or a history of MYOCARDIAL INFARCTION.

299+ PubMed studies analyzed · 61 RCTs · Evidence Score: 58

Research Domains

Ticagrelor has been studied across 18 research domains including ❤️ Cardiovascular, 🔬 Oncology, 🔥 Metabolic, ⚡ Energy & Fatigue, 😴 Sleep. The primary research focus is ❤️ Cardiovascular with 21% of studies addressing this area.

Similar Compounds by Shared Targets

The following compounds share molecular targets with Ticagrelor, based on binding affinity data from BindingDB and ChEMBL. Sorted by shared target overlap.

darapladib
11 shared targets
Benzethonium
14 shared targets
2-Methoxyestradiol
10 shared targets
Dequalinium
13 shared targets
Demeclocycline
6 shared targets
Thiorphan
6 shared targets
Vemurafenib
11 shared targets
Canagliflozin
6 shared targets
propionylpromazine
9 shared targets
Estrone
8 shared targets
Loading evidence profile...

This evidence profile for Ticagrelor is generated deterministically from 299 PubMed-indexed studies. All data is corpus-verified with Merkle proofs. BiohacksAI does not provide medical advice. Always consult a healthcare professional before starting any supplement regimen.

Data source: PubMed/MEDLINE (NLM). Corpus version: current. Patent pending (EVE-PAT-2026-001). © 2026 Organiq Sweden AB.